Hormonal
Treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists (exenatide or liraglutide) at clinically relevant doses for at least 20 weeks results in significant weight loss in overweight or obese patients, regardless of type 2 diabetes status.
If you are overweight or obese, GLP-1R agonists like exenatide or liraglutide are proven to help you lose weight, even if you don't have diabetes. You take them by injection (daily or weekly), and while you might feel nauseous at first, this usually passes. The average weight loss is around 3 kg, which is clinically significant. Talk to your doctor about whether these are right for you.
The present review provides evidence that treatment with GLP-1R agonists leads to weight loss in overweight or obese patients with or without type 2 diabetes mellitus.
Why this rating
Systematic review and meta-analysis of 25 randomized controlled trials with robust statistical methods.
Source
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsbøll et al. · BMJ · 2012
DOI 10.1136/bmj.d7771
More from this paper
- GLP-1R agonists improve cardiovascular risk factors by reducing systolic and diastolic blood pressure and total cholesterol concentrations.Weak
- GLP-1R agonists improve glycaemic control in patients with type 2 diabetes by reducing HbA1c and increasing the proportion of patients achieving target HbA1c levels, without causing significant hypoglycemia.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →